MedTrace Logo

QuadraMune(TM) for Prevention of COVID-19

NCT04421391 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2020-06-09

No results posted yet for this study

Summary

QuadraMune(TM) is a nutritional supplement which has previously been demonstrated to possess antiinflammatory and immune modulatory activity based on in vitro and pilot in vivo studies. The current clinical trial aims to assess in a 500 volunteer trial the efficacy of QuadraMune(TM) in reducing infection in individuals at high risk of COVID-19.

Conditions

  • Covid19
  • Coronavirus
  • SARS-CoV 2

Interventions

DIETARY_SUPPLEMENT

QuadraMune(TM)

QuadraMune(TM) is a commercially available nutritional supplement

Sponsors & Collaborators

  • Therapeutic Solutions International

    lead INDUSTRY

Principal Investigators

  • James Veltmeyer, MD · Therapeutic Solutions International

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-08
Primary Completion
2020-11-01
Completion
2020-11-08

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04421391 on ClinicalTrials.gov